BWAY logo

BRAINSWAY LTD-ADR

BWAYNASDAQ
US Equity
$11.92▲ $0.50 (+4.38%)
Pre-market · at close
🔔
Track BWAY
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.4%
7d▲ 6.0%
14d▲ 4.4%
30d▼ 9.8%
ytd▲ 25.0%
1y▲ 44.1%
🏦Market Cap
$480M
Small Cap
📈Revenue Growth (YoY)
27.1%
High Growth
📊Gross Margin
74.9%
High
💵FCF Margin
24.9%
Strong
⚖️P/S Ratio
9.3x
Elevated
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$11.84 – $11.99
52-Week Range
$2,391.00 – $5,123.00
Volume (shares)
3,689
Avg Volume (shares)
—
Shares Outstanding
40.3M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$52M
Last Q Revenue
$17M
P/E Ratio
52.1
P/S Ratio
9.3x
EPS (TTM)
$0.23
Dividend Yield
—
Dilution (1yr)
−44.3%
BWAY logo

BRAINSWAY LTD-ADR

BWAY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$52M▲ +27.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
75.4%▲ +1.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$4M▲ +210.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$16M▲ +152.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21.0M▼ −44.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$61M▼ −$3M YoY
StockOtter · stockotter.space

About BRAINSWAY LTD-ADR

BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.